Express Pharma

MAY 5, 2025

GlobalData projects 44 new TCI drug approvals by 2029, with 18 expected in 2027 alone. Tokali adds, CAR-T therapies are at the forefront of T-cell immunotherapy, but the entire space, including TCR-based therapies, is advancing rapidly.

64

64

European Pharmaceutical Review

JUNE 9, 2025

billion annually in 2029 will enhance Britain’s leading position in research and innovation, according to the Department for Science, Innovation and Technology (DSIT) and government MPs. The review will specify how the government is planning to invest in Britain’s renewal, which helps to drive its Plan for Change.

Packaging 52

Packaging 52

Pharmaceutical Technology

JULY 1, 2025

If there is a quick agreement with an expectation for changes to be implemented around 2029, Olteanu says crucial investment decisions can be made while considering the Pharma Package as investment remains one of the key challenges holding Europe back from its dreams of global competitiveness.

Packaging 52

Packaging Drug Development Chemotherapy Biosimilars 52

Pharmaceutical Technology

JULY 4, 2025

Other drugs are set to face competition too, with both MSD’s Keytruda (pembrolizumab) and Johnson & Johnson’s (J&J) Darzalex/Faspro (daratumumab and hyaluronidase-fihj) losing US exclusivity by 2029, representing a particular headwind in oncology.

Biosimilars 52

Biosimilars Chemotherapy Packaging Communication 52

Express Pharma

MARCH 4, 2025

per cent from 2025 to 2029. The global Sugammadex market, valued at approximately 1.53 billion in 2023, is projected to grow at a CAGR of 8.5 per cent, reaching $ 2.89 billion by 2031. Overall, the pharmaceutical market in the ASEAN region is projected to grow at a CAGR of 4.83

66

66

BioPharma Dive

JULY 2, 2025

The company had hoped to kick off Phase 3 research in 2026 and launch the medicine around 2029. Chief Executive Kevin Ali called the drug a “multibillion dollar opportunity” during the J.P. Morgan Healthcare Conference in January. Organon acquired the drug in its purchase of Forendo Pharma in 2021.

Drug Pricing 96

Drug Pricing Drug Development Vaccines 96

Pharmaceutical Technology

JULY 1, 2025

According to William Blair, forecast revenue rate from 2024 to 2029 growth rate for AbbVie trails only Eli Lilly and Sanofi, representing an “attractive opportunity” for long-term investors.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Packaging Communication Hospitals 52

Pharmaceutical Technology

JUNE 30, 2025

The facility will be complete and ready for media fill by late 2029, with plans to move Vetter’s existing clinical operations in Skokie. The planned 160,000ft² facility will focus on aseptic production and includes areas for material preparation and compounding. Further supporting buildings will have storage spaces, laboratories and offices.

Packaging 52

Packaging Hospitals Compounding Communication 52

Pharmaceutical Technology

JULY 14, 2025

A report by UNAIDS predicts that six million new HIV infections and four million AIDS-related deaths could occur between 2025 and 2029 if US-supported HIV treatment and prevention services collapse.

Vaccines 52

Vaccines Packaging Hospitals Communication 52

Pharmaceutical Technology

JUNE 26, 2025

For example, the rheumatoid arthritis drug market across the eight major global markets is forecast to reach $29.1bn by 2029, according to analysis by GlobalData. Sanofi’s blockbuster autoimmune drug Dupixent (dupilumab) is one of the best-selling drugs in the world, representing the lucrative nature of the sector.

Packaging 52

Packaging Communication Hospitals Drug Development 52

FDA Law Blog: Biosimilars

DECEMBER 23, 2024

Earlier in the week, it was reported that there was a bipartisan agreement on a bill that would have funded the government and extended the first sunset date for the rare pediatric disease priority review voucher program for nearly 5 years, until September 30, 2029.

Drug Development 59

Drug Development 59

Beckers Hospital Review

JULY 9, 2025

By June 30, 2029, hospitals must offer prices at or below the statewide hospital price average. Rather than offering traditional health plans, employers can contract directly with the hospitals, tying health benefits to the capped prices. Failure to comply could result in losing nonprofit status for at least one year.

Hospitals 77

Hospitals Inpatient 77

Big Molecule Watch

JANUARY 13, 2025

Also on January 14, Celltrion is pitched to highlight three ADC drugs and three multispecific antibody drugs currently under development (with targeted commercial launch by 2029).

Biosimilars 59

Biosimilars 59

Pharmaceutical Technology

JUNE 25, 2025

The regulation came into force in March 2025; however, it has not yet come into application, with this set to happen in March 2029. The European Commission (EC) faces a March 2027 deadline to adopt several key implementing acts, which will lay out detailed rules for putting the regulation into practice.

Communication 52

Communication Hospitals Packaging Pharmaceutical Companies 52

FDA Law Blog: Biosimilars

OCTOBER 13, 2024

This bill would extend the designation deadline until September 30, 2029, a five-year extension (and would require yet another GAO report). It was shortly thereafter introduced in the Senate and referred to the Committee on Health Education, Labor, and Pensions, where it remains.

Documentation 65

Documentation Drug Development 65

Pharmaceutical Technology

JUNE 16, 2025

Find out more According to GlobalData’s Acute Lymphocytic Leukemia: Epidemiology Forecast to 2029 report, the number of diagnosed incident cases in the eight major markets (8MM: China, France, Germany, Italy, Japan, Spain, the UK and the US) is projected to increase from 25,636 in 2025 to 26,482 by 2029 at an annual growth rate of 1.16%.

Labelling 52

Labelling Communication Hospitals Vaccines 52

Beckers Hospital Review

JUNE 27, 2025

The 27-acre campus is slated to be completed in 2029 and will replace the system’s current hospital in downtown Charleston. billion Northeast Houston Hospital by early 2029. based Kaiser Permanente broke ground on a $1 billion hospital campus in Sacramento, expected to open in 2029. Francis Healthcare broke ground on a $1.2

Hospitals 59

Hospitals 59

Pharmaceutical Technology

JUNE 11, 2025

The UK’s National Health Service (NHS) is receiving a £29bn ($39.1bn) funding boost, reflecting a 3% annual rise on current levels over the next three years to reach £226bn ($305.7bn) by 2029.

52

52

STAT

SEPTEMBER 18, 2024

A House committee on Wednesday passed a bill to renew a program aimed at aiding development of drugs for rare diseases in children , putting it in a better position to be added to government funding legislation.    The pediatric rare disease priority review voucher program is set to end on Sept.

326

326

STAT

OCTOBER 31, 2023

Later, Amgen reworked old patent applications and, by doing so, succeeded in extending patent protection for the medicine from 2019 until 2029, according to an analysis by the advocacy group. Continue to STAT+ to read the full story…

Drug Pricing 328

Drug Pricing 328

Express Pharma

OCTOBER 10, 2023

Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio, with anticipated sales surpassing $7 billion and a 48 per cent market share of small molecules in lung cancer treatment by 2029, according to GlobalData. It is anticipated to generate $361 million in sales for lung cancer treatment by 2029.

102

102

European Pharmaceutical Review

AUGUST 9, 2023

Future of the antibody-drug conjugate therapy market By 2029, the global market for ADC therapies in oncology is expected to be worth more than $36 billion, the research predicted. Pfizer to acquire Seagen for $43 billion The post ADC oncology therapy market to value over $36b by 2029 appeared first on European Pharmaceutical Review.

98

98

Express Pharma

JUNE 13, 2024

billion in 2029, forecasts GlobalData. bn in 2029: GlobalData appeared first on Express Pharma. The key opinion leaders (KOLs) interviewed by GlobalData identified the greatest unmet needs within the ALS space. per cent and therefore, the opportunity within the space will parallelly grow,” concludes Ali.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Compounding 98

Pharma Times

MAY 28, 2024

The MRC BRC and the MDU will use the funding and cutting-edge research to improve public health until March 2029

146

146

STAT

JUNE 25, 2024

The company said that it expects to add 1,000 new jobs, and that construction will gradually be finalized between 2027 and 2029. Novo Nordisk said the new facility would expand over 56 acres and add 1.4 million square feet of production space, doubling the combined square footage of the other three facilities in North Carolina.

266

266

STAT

SEPTEMBER 19, 2024

House committee passed a  bill  to renew a program aimed at aiding development of drugs for rare diseases in children, putting it in a better position to be added to government funding legislation , STAT reports. The pediatric rare disease priority review voucher program is set to end on Sept.

Compounding 254

Compounding Compounding Pharmacies Packaging 254

Express Pharma

SEPTEMBER 24, 2023

billion by 2029, reflecting a robust 55 per cent compound annual growth rate (CAGR). billion in sales in 2029. billion in sales in 2029. billion in sales in 2029. bn in 2029: GlobalData appeared first on Express Pharma. The psychedelic drug market is on the brink of extraordinary growth, projected to soar to $7.2

Drug Development 52

Drug Development Compounding 52

The Pharmacist

MAY 21, 2024

The commitment came as part of the Welsh Government’s Strategic Workforce Plan for Primary Care for 2024/25-2029/30, published last week. The plan also committed […] The post GP pharmacists in Wales to get structured induction programme appeared first on The Pharmacist.

Pharmacy Technician 136

Pharmacy Technician 136

Pharmaceutical Technology

FEBRUARY 8, 2024

In recognition of its 30th anniversary, the International Gaucher Alliance (IGA) unveiled a visionary five-year strategic plan extending to 2029.

52

52

pharmaphorum

NOVEMBER 21, 2024

Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets

98

98

Express Pharma

SEPTEMBER 4, 2023

SB5 is set to become a leading biosimilar for this debilitating, chronic condition, with a global sales forecast of $832 million by 2029, according to GlobalData. The post Humira biosimilar to see $832 million in sales by 2029: GlobalData appeared first on Express Pharma.

Biosimilars 52

Biosimilars 52

Express Pharma

SEPTEMBER 30, 2024

million by 2029, the approval of carboplatin aims to strengthen Venus Remedies’ position in the African oncology market. The authorisation of bortezomib aims to enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia. In Morocco, where the oncology drug market is set to reach $150.8

105

105

Express Pharma

DECEMBER 3, 2023

GlobalData anticipates the drug to earn $483 million by 2029. billion by 2029. Following the news that AbbVie has agreed to buy biotech ImmunoGen , the maker of the FDA-approved ovarian cancer treatment Elahere, for $10.1 With the deal, AbbVie joins the other major pharma companies investing billions in ADC programs.

110

110

Express Pharma

FEBRUARY 21, 2024

billion by 2029. “ billion in 2023, and GlobalData projects it to surpass $14 billion by 2029. The ADC contains an anti-TROP2 monoclonal antibody covalently linked to the topoisomerase I inhibitor cytotoxic payload. GlobalData estimates the drug to earn $3.12

Chemotherapy 111

Chemotherapy Labelling Immunization Immunity 111

European Pharmaceutical Review

FEBRUARY 20, 2024

million by 2029. percent between 2022 and 2029. A report from Data Bridge Market Research has predicted that the upstream bioprocessing market will value $14,256.78 Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85

Process Improvement 98

Process Improvement Biosimilars Drug Development 98

Express Pharma

NOVEMBER 12, 2023

million cases in 2029, equating to an annual growth rate of 6.46 million cases in 2029, equating to an annual growth rate of 2.71 According to GlobalData’s Pharmaceutical Intelligence Center, the diagnosed prevalent cases of NASH in India are projected to increase from 10.7 million cases in 2023 to 12.6 million cases in 2023 to 6.5

Diabetes 105

Diabetes 105

Express Pharma

DECEMBER 28, 2023

According to GlobalData estimates, the global CGT market is projected to reach $80 billion by 2029. Oncology is expected to continue its lead as the indication and area of major development for cell and gene therapies, accounting for 44 per cent of the CGT market by 2029.

Drug Development 105

Drug Development 105